CC 49716/2024

—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL

Parent infringement case:UPC CFI 145/2024

Case details: Status
—
Action
Counterclaim for revocation
Category
Counter Claim for Revocation
Parties: Claimants
Accord Healthcare S.L.U.
Accord Healthcare GmbH
Accord Healthcare B.V.
Accord Healthcare Italia Srl
Accord Healthcare AB
STADAPHARM GmbH
STADA Arzneimittel AG
STADA Nordic ApS
Reddy Pharma SAS
betapharm Arzneimittel GmbH
Dr Reddy's Srl
Zentiva France
Zentiva Pharma GmbH
Zentiva, k.s.
Reps: Frédéric Chevallier (Herbert Smith Freehills Kramer LLP)
Respondents
Sanofi SA (successor of Sanofi Mature IP)
Sanofi Winthrop Industrie
Sanofi-Aventis GmbH
Sanofi Belgium
Sanofi-Aventis Deutschland GmbH
Sanofi S.r.l.
Sanofi B.V.
Sanofi - Produtos Farmaceuticos Lda
Sanofi AB
Sanofi A/S
Reps: Jules Fabre (Pinsent Mason); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing)
Division: Munich LD
Judges: —
Technology: Pharmaceuticals · Oncology · Pharmaceutical & Medical
Language: —
First decided: Jan 24, 2025

Decisions

2025-01-24
Counterclaim for revocation
The Munich Local Division issued a procedural order in the infringement actions by Sanofi (and successor entities) against multiple generic pharmaceutical companies (Accord, STADA, Dr Reddy's, Zentiva) concerning EP 2 493 466 (UPC_CFI_145/2024 and related cases). The order concerns case management — identifying parties and representatives across the eight consolidated cases relating to counterclaims for revocation.
Legal issues:Procedural case management across consolidated actionsCounterclaim for revocation in pharmaceutical patent infringement

Documents